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The importance of the AKR mouse strain in leukemia research is widely recognized. 
Leukemia develops in 80-90% of AKR mice with a peak incidence at 8 mo of age and 
this characteristic has been maintained since the strain was derived by Jacob Furth 
in 1935 (1). Study of AKR mice allowed Furth and his coworkers  (2) to discover the 
essential role of the thymus in leukemia development and led Gross (3)  to his dis- 
covery of the murine leukemia virus. Newer immunological  and virological techniques 
capable of tracing virus and viral antigens in AKR mice are now providing the basis 
for defining the genetic determinants of virus transmission and viral gene expression 
(4, 5). 
One of the widely held views of experimental tumor immunology some years back 
was that the AKR mouse (before as well as after leukemia development) was immuno- 
logically tolerant of the various antigens associated with its indigenous leukemia virus 
(6). This conclusion was based on what appeared at the time to be substantial evi- 
dence. From birth to death, AKR mice possess the spectrum of cellular (7), viral (8), 
and soluble antigens (9)  that  accompany infection with wild-type Gross leukemia 
virus. Characteristic C type virus particles could be visualized budding from normal 
and neoplastic cells and RNA leukemogenic virus could be isolated throughout the 
life-span of the mouse. Antibody against cellular and soluble antigens could not be 
detected in the blood of AKR mice at any age (10), nor could transplantation resist- 
ance to syngeneic tumor cells be clearly demonstrated (11). We now know from the 
work  of  Oldstone  et  al.  (12)  and  Mellors  et  al.  (13)  with  murine  leukemia 
virus (MuLV)  1 that the presence of virus and viral antigens throughout life, and the 
failure to detect antibody in the serum of infected mice, do not exclude the occurrence 
of a specific immune response. Specific antibody can be demonstrated in the glomeruli 
of  infected  mice,  trapped  there  presumably as  antigen-antibody complexes.  The 
absence of readily demonstrable serum antibody in AKR mice can be ascribed to the 
relative rates of antigen and antibody production, synthesis and release  of virus and 
viral antigens evidently surpassing the production of antibody. But despite the pres- 
ence of  an immune response  to  at  least  some  MuLV-associated antigens in AKR 
mice, it is not an effective  one in terms of virus suppression or inhibiting the growth 
of leukemic cells, so far as we can tell. 
1 Abbreviations used in this paper: CNV, composite numerical value; CVF, cobra venom 
factor; MuLV, murine leukemia virus. 
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The work to be recorded here had its origin in the studies of Graft et al. (14) 
on the effect of interferon in AKR mice with  spontaneous leukemia. Marked 
reduction in the size of leukemic lymph nodes and spleens occurred within 18- 
24 h  after interferon injection.  Morphological evidence for destruction of leu- 
kemia cells could be seen at 21/4 h  by light microscopy and as soon as 30 rain 
by electron microscopy (15). The cytotoxicity appeared to be selective for leu- 
kemia cells, normal lymphocytes apparently remaining intact and uninjured. 
Two  observations  suggested  that  the  effect is  not  due  to  a  direct  cytotoxic 
action of interferon on leukemia cells. First, the viability and metabolic activity 
of AKR leukemia cells in vitro is not influenced by added interferon.  Second, 
the serum of interferon-treated AKR mice with leukemia (at a time when inter- 
feron has been cleared from the blood) is itself capable of causing striking re- 
duction  in  leukemic lymph  nodes  and  spleens  of other  AKR  leukemic mice 
(16). 
We have now found that normal serum from a variety of species, including 
the  mouse,  mimics  the  effect of interferon  on AKR  leukemia.  The  evidence 
obtained, so far, points to a component of the complement system as the anti- 
leukemic factor in normal serum. 
Materials and Methods 
Infusion  Technique.--Intravenous  infusion in the mouse is readily  accomplished through 
the tail vein, providing that immobilization of the tail is maintained. This can be done without 
anesthesia by the use of a conical wire cage attached to a plastic "paddle shaped" base (Fig. 1). 
The mouse is placed in the wire cage and the tail is immobilized by fixing it in position on the 
"paddle handle" with one-half inch masking tape at the distal end. Motion is further limited 
by a  small strip of tape across the base of the tail.  To cannulate the tail vein, the vein must 
be dilated  and this is done either before placing the mouse in the cage  (by dipping the tail 
into warm water)  or after  restraining the animal  (by applying a  warm gauze pad over the 
vein).  A  27 gauge needle attached to the  10 ml plastic syringe by silicone rubber tubing is 
used to cannulate the vein and is fixed in position by tape coming up from under the "paddle 
handle." If more than one infusion of the same animal is planned, the needle should be inserted 
in the most distal portion of the vein and care should be taken when removing the needle to 
prevent trauma to the vein. Rate of infusion is controlled by a  Varioperpex peristaltic pump 
(LKB, Bromma 1, Sweden), with input delivery set at 1 ml/15 rain. Material to be tested was 
diluted to 6  ml in pyrogen-free normal saline and, at this rate, infusion was completed in 90 
rain. It is possible to extend this period to as much as 7.5 h  (without undue harassment to the 
mouse) by means of the variable speed available on the pump. 
Serum.--Female Swiss  mice  (obtained  from  Charles  River  Breeding  Laboratories,  Inc., 
Wilmington, Mass.)  and  mice of inbred  strains  (from  Jackson  Memorial Laboratories,  Bar 
Harbor, Me. or from our colonies) aged 3-8 mo were anesthetized with ether and bled from the 
tail. Normal and C4-deflcient guinea pigs (supplied by Dr. I. Green, Division of Immunology, 
National  Institutes of  Health,  Bethesda,  Md.)  were  bled  by cardiac  puncture while  under 
light ether anesthesia. Horse, rabbit,  and human sera were obtained by venepuncture. Blood 
was collected in pyrogen-free bottles and was allowed to clot for 1-2 h  at room temperature. 
Ceils were removed by centrifugation at 650  X  g at 4°C and the serum was aliquoted in vol- 
umes adequate for administration to several mice and stored at  --78°C. Samples were thawed 
just before use and were not refrozen. Individual mice were infused with 1.5 ml mouse serum, 
0.5  ml human serum, cr 0.75  ml guinea pig serum or horse serum; the sera were diluted to 
6  ml with pyrogen-free normal saline immediately before infusion. KASSEL~ 0LD~ CARSWELL~ FIORE~ AND  HARDY  927 
FIG. 1.  Procedure for tail vein infusion in the mouse. Wire mesh cone attached to plastic 
paddle restrains mouse for intravenous infusion. Rate  of infusion controlled by peristaltic 
pump (see text for details). 
Evaluation  of Leukemic Mice.--A large colony of retired AKR/JAX female breeders served 
as a source of leukemic mice. The mice were examined weekly for the development of lymph- 
adenopathy and splenomegaly. The degree of enlargement of the (a)  inguinal,  (b) cervical, 
and  (c)  mesenteric lymph nodes, and  (d)  spleen were scored from 1  +  to 4  +  on the basis of 
palpation. The sum of these four scores is called the composite numerical value  (CNV) and 
was used to evaluate changes in the leukemic mouse brought about by treatment. Thus, the 
percentage reduction in  CNV is equal to  100  -  (CNV at  24 h  postinfusion/CNV before 
infusion X  100). The subjective limitations of this evaluation are such that a  reduction of 
less than 20% in the size of the lymph nodes and spleen was not considered significant. 
Thymic enlargement was suspected when evidence of respiratory distress, bowing of the 
chest, and characteristic hunching was observed. This parameter could not  be accurately 
evaluated  I but was noted as an indication of greater disease involvement than was numerically 
recorded. Animals were  examined frequently during the infusion and  postinfusion period, 
and CNV estimated at 24 and 48 h after completing the infusion. 
Interferon.--The  preparation of tissue culture interferon has been described in previous 
reports (14, 16). Briefly,  mouse cells (L929) grown in suspension culture were infected with 
Newcastle disease virus. Mter an 18 h incubation period, cold ethanol was added to the cell- 
free culture medium and the precipitate dialyzed against 2% acetic acid. The resulting material 
was frozen, lyophilized, and taken up with heat-inactivated horse serum. Antiviral activity 
was assayed on L929 monolayers challenged with vesicular stomatitis virus. Mice were infused 
with 2,500-5,000  U of interferon in 6 ml of normal saline. 
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Laboratories, Detroit, Mich.  Stock preparations of  1,000 #g/ml were  dissolved  in normal 
saline and stored at --20°(2. A series of preliminary experiments showed that the infusion of 
endotoxin at 10/~g (in 6 ml saline) caused greater than 50% reduction of CNV in leukemic 
AKR mice. 
Cobra Venom Factor (CVF) (see  ref. 17, 18).--Lyophilized CVF was purchased from Cordis 
Laboratories, Miami, Fla. It was reconstituted in cold distilled water to a concentration of 
100 U/ml, subaliquoted and stored at --78°C.  For in vitro decomplementation,  serum was 
diluted to 6 ml with normal saline (see above) and incubated with 10 U of CVF/ml of serum 
at 37°C for 30 rain.  For in vivo decomplementation,  AKR leukemic mice were injected i.v. 
with 50 U CVF 18 h before infusion with serum, interferon,  or endotoxin. 
Complement Components (19, 20).--Individual complement components  from  human and 
guinea pig were purchased from Cordis Laboratories. They were reconstituted with cold dis- 
tilled water, aliquoted, and stored at --78°C.  Each of the components was tested by infusing 
leukemic mice with 500 CHS0 U diluted to 6 ml in normal saline. Individual components  are 
reported by Cordis to contain less than 10 CH50 U/ml of contamination by other complement 
components. 
RESULTS 
Infusion of Normal Mouse Serum.--AKR mice with advanced leukemia were 
infused with serum from random-bred Swiss mice or from mice of seven different 
inbred strains. The strains selected represent those with the complete spectrum 
of  complement  components  in  their  serum  (Swiss,  C57BL/6,  B10D2  new, 
SJL/J) and those lacking the C5 component of the complement system (AKR, 
A, B10D2 old, DBA/2). 
Fig. 2 shows that serum from C5  + mouse strains can cause a  striking reduc- 
tion in the size of lymph nodes and spleen in leukemic mice, whereas the serum 
of  C5-deficient mice  was  generally ineffective.  The  antileukemic  activity of 
serum  from  Swiss  mice  was  generally greater  than  serum  from  C5  +  inbred 
strains.  Infusion  of normal  saline under  comparable  conditions produced  no 
change in leukemic mice. 
Fig. 3 illustrates the effect of an infusion of Swiss mouse serum on a leukemic 
AKR mouse. Within 24 h  there is a  marked reduction in the size of leukemic 
lymph nodes and spleen. Microscopic evidence of leukemia cell destruction can 
be seen as early as 11/~ h  postinfusion (Fig. 4) and by 3 h  phagocytosis of de- 
generating  let~emia  cells is  evident.  Destruction  of  leukemia  cells was  also 
observed in blood smears from animals with circulating leukemia cells. Within 
1-2  h  after  infusion  of  Swiss  mouse  serum,  cytoplasmic  vacuolization  and 
nuclear pyknosis and fragmentation were observed in peripheral leukemia cells, 
and this was followed by a marked drop in the peripheral white cell count. 
Infusion of IIeterologous Serum.--Serum  from normal guinea pigs, horses, or 
humans  causes  leukemia  cell  destruction  and  shrinkage  of  leukemic  lymph 
nodes  and  spleen when  infused in AKR  leukemic mice  (Fig. 5).  Serum  from 
C4-deficient guinea pigs was comparable to serum from normal guinea pigs in 
antileukemic  activity.  Serum  from  normal  or  C6-deficient rabbits  (obtained 
from  Rancho  de  Conejo,  Vista,  Calif.) proved  too  toxic  to  evaluate  even  at 
levels of 0.1  ml/mouse.  Removal of the naturally occurring heteroantibodies KASSEL,  OLD, CARSWELL, FIORE,  AND  HARDY  929 
~ -100  - 
-80 - 
"i -40 
i .o,  Ii  ItL 
1  Swiss  1571L.,'611001  SJL/J  A  AIR 
new 
L.  (17)  (9)  (10)  (12))  L(IO)  (11)  t ILL 
11012  DBA/I  Swiss  Swiss  Swiss  Swiss 
old  by  A56%  +  tumor- 
injection  CVF  bearing 
(10)  (9) j  (11)  (10)  (10)  (13) 
Fzo. 2.  AKR leukemic mice infused with normal serum from C5  + and C5- mouse strains. 
Mice evaluated at 24 h postinfusion  (see text for details). Reduction >20% considered  sig- 
nificant.  Number  in parenthesis indicates number  of  leukemic  mice  tested.  Results: C5  + 
mouse  serum  causes  reduction in leukemic  lymph nodes  and spleens.  C5- mouse  serum  is 
inactive. The antileukemic factor in Swiss mouse serum is (a) not demonstrable by injection 
(in contrast to infusion),  (b) heat labile, (c) inactivated by CVF in vitro, and (d) reduced in 
tumor-bearing mice. 
in rabbit serum by absorption with mouse tissues (as in the preparation of com- 
plement for cytotoxic tests with mouse  cells [21])  removed  the acute  toxicity 
for  leukemic  mice.  Such  absorbed  serum  demonstrated  good  antileukemic 
activity. 
Injection  vs. Infusion of Serum.--We did not observe any antileukemic effect 
when the mouse, horse, or human serum was given as a  single injection, rather 
than  by infusion  (Fig. 2). Injection of undiluted serum  (i.v. or i.p.)  or serum 
diluted to 6 ml with normal saline (i.p.) in amounts that were highly effecti~;e 
by infusion gave no reduction of leukemic lymph nodes or spleen. 
Effect of Heat Inactivation.--The  antileukemic property of Swiss serum was 
abolished by preincubating the serum at 56°C  for 30 rain, a  procedure known 
to  inactive  certain  components  (including  C5)  of  the  complement  system 
(Fig. 2).  Similarly, the activity of horse and human serum in leukemic mice is 
also markedly reduced after heat-inactivation (Fig. 5). 
Toxicity  and Subsequent Fate of Infused Leukemic Mice.--Infusion  of saline, 
C5-deficient normal mouse serum, or heat-inactivated homologous or heterolo- 
gous serum was tolerated with little toxicity. Mice receiving C5  + serum showed 
varying degrees of lethargy, ruffled coat, and decreased food intake during the 
12-24 h postinfusion period. In general, signs of toxicity paralleled the observed FIG.  3.  AKR mice with spontaneous leukemia.  (a)  Untreated leukemic mouse with mas- 
sively enlarged mesenteric lymph nodes (arrow)  and spleen. (b) A  leukemic mouse with com- 
parably  advanced  disease that  had  been infused with serum from  normal  Swiss mice 24  h 
previously; marked reduction in size of mesenteric lymph nodes  (arrow)  and spleen. 
930 FIG. 4.  Mesenteric lymph nodes of leukemic  AKR mice.  (a)  Untreated leukemic mouse. 
Lymph node replaced by proliferating leukemic lymphoblasts. (b) Leukemic mouse 11,4 h after 
infusion with serum from normal Swiss mice.  Lymph node in initial phase of leukemia cell 
destruction. Magnified 400  X. 
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FIo.  5.  AKR  leukemic mice infused with  normal serum from  heterologous  species  (see 
Fig. 2 and text for details). Results: Horse, human, and guinea pig serum cause reduction in 
leukemic lymph nodes and spleen. The antileukemic factor is (a) heat labile (horse and human 
serum) and (b) inactivated  by CVF in vitro (human serum). 
reduction  of  leukemic  lymph nodes  and  spleen.  C5  +  mouse  serum  produced 
less toxic effects than heterologous serum.  Within  24-36 h, all toxicity associ- 
ated with  serum infusion disappeared.  By the fifth day postinfusion,  a  resur- 
gence of disease was observed in most leukemic mice. 
Infusion  of Serum from  Tumor-Bearing  Mice.--Serum  was  collected  from 
Swiss  mice  that  had  received  transplants  of Ehrlich  ascites  or Tupper  liver 
tumor  (i.p.  or  s.c.)  7-8  days  previously.  In contrast  to serum  from  normal 
Swiss mice, infusion of serum from tumor-bearing Swiss mice caused no reduc- 
tion in the size of leukemic lymph nodes or spleen  (Fig. 2). 
Effect  of Cobra Venom Factor.--Incubating  Swiss  mouse  serum  or  human 
serum  with  CVF in vitro  before infusion  into  leukemic  AKR mice abolished 
the antileukemic activity of these sera (Figs. 2 and 5). Similarly, leukemia cell 
destruction did not occur if leukemic animals were injected with CVF 18-20 h 
before the infusion of Swiss mouse serum. 
Effect  of  Interferon.--As  in  previous  studies  (16),  infusion  of  interferon 
caused a marked reduction in the size of lymph nodes and spleen  (Fig. 6). Pre- 
incubating  the interferon preparation  with  CVF before infusion  did not alter 
its antileukemic activity. If on the other hand, CVF was given to the leukemic 
mouse  18-20 h  before interferon,  then  interferon  caused no reduction  of leu- 
kemic lymph nodes or spleens at 24 h  postinfusion  (Fig. 6). At 48 h, however, 
interferon-mediated  destruction  of leukemia  cells had  occurred,  showing  that 
the action of interferon had been delayed but not abolished by CVF. 
Effect of Endotoxin.--Infusion  of 10 #g of endotoxin caused marked reduction 
in the size of lymph nodes and spleen (Fig. 6). Characteristic endotoxin toxicity KASSEL,  OLD, CARSWELL,  FIORE~ AND  HARDY  933 
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FIG. 6.  AKR leukemic mice infused with interferon and endotoxin (see Fig. 2 and text for 
details). Results: Interferon (5,000  IU) and E  coli endotoxin (10 #g) cause reduction in leu- 
kemic lymph nodes and spleens within 24 h.  Pretreating leukemic mice with CVF  (50 U) 
delays the antileukemic effect of interferon and endotoxin by 24 h. 
accompanied the leukemia cell destruction--diarrhea, prostration, and weight 
loss  (2-3  g  over a  24-36 h  period).  These toxic manifestations  disappeared 
within  2-3  days  after endotoxin treatment.  As  with  interferon (see above), 
pretreating the mouse with CVF delayed, but did not abolish, the antileukemic 
effect of endotoxin  (Fig.  6).  Preincubating endotoxin with  CVF  in vitro or 
heating endotoxin to 56°C for 30 min did not alter its antileukemic activity. 
Endotoxin toxicity was  markedly reduced in  leukemic mice pretreated with 
CVF. 
Antileukemic Activity of Individual-Complement Components.--Nine comple- 
ment  components from guinea pig serum  and nine from human  serum  were 
tested individually by infusion in  AKR  leukemic mice  (Fig.  7).  C5  of both 
guinea pig and human origins stood out as giving consistent reduction of leu- 
kemic nodes and spleen. The other complement components were generally in- 
effective. The  antileukemic  activity  of  the  C5  preparations  showed  a  dose 
dependence over the range of 200 U/mouse to 2,000 U/mouse. Infusion of C5 
(in  comparison  to  injection)  was  necessary  to  demonstrate  the  C5  effect. 
Heating the C5 to 56°C for 30 rain abolished its antileukemic activity. 
DISCUSSION 
The  infusion  of  normal  serum  from  homologous  or  heterologous sources 
leads to the rapid destruction of leukemia cells.  The fact that this is observed 
in mice with spontaneously developing leukemia adds considerable significance 
to the observation. Prolonged infusion of the serum is critical in demonstrating 934  SERUM-MEDIATED  LEUKEMIA  CELL  DESTRUCTION 
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FIG. 7.  AKR leukemic mice infused with complement components from guinea pig serum 
and from human serum. Each of the complement components was tested  in four AKR leu- 
kemic mice; the findings for individual components from the two species were identical and 
were therefore plotted together (see Fig. 2 and text for details). Results: C5 is the antileukemic 
complement component in normal guinea pig and human serum. 
the  effect.  Comparable  amounts  of serum  given  by injection  rather  than  by 
infusion  were inactive,  a  likely reason why the phenomenon has not been ob- 
served before. 
Present  evidence points to a  component of the complement system as medi- 
ating the effect. The findings underlying this conclusion are as follows: 
(a)  CVF abolishes  the  antileukemic  effect of normal  serum.  CVF depletes 
complement by activating C3, thereby setting off the step-by-step consumption 
of C3 -~ C9 terminous  (17). The ability of CVF to cancel the serum-mediated 
lysis of leukemia cells was shown in two ways: preincubating serum with CVF 
before infusion  or pretreating  leukemic mice with  CVF before infusing active 
serum. 
(b)  Leukemia  cell  destruction  was  induced  by  serum  from  mouse  strains 
possessing all  components of the  complement system but not by serum  from 
mice with  genetically determined  deficiency of C5.  So far,  eight  strains  have 
been tested and the correlation with the C5 trait has been consistent. 
(c)  Fractions  rich  in  C5  from  both  human  and  guinea  pig  ~erum  showed 
antileukemic activity, whereas other C fractions (C1-4 and C6-9) were without 
effect. As AKR mice are  genetically C5-deficient  (22-24),  it may not be sur- 
prising that  the  antileukemic-complement  component in normal serum  is  C5. 
Apparently  C4 is  not  generally  limiting  in  the  leukemic  mouse;  C4-deficient 
guinea  pig  serum  was  essentially  equal  to  nondeficient  guinea  pig  serum  in 
antileukemic activity. 
How does  C5 bring, about  leukemia  cell destruction  in AKR mice? For the 
sake of discussion,  we can put forward three possibilities: 
(a)  C5 has a direct e~ect on leukemia cells by providing the missing complement KASSEL,  OLD, CARSWELL,  FIORE,  AND  HARDY  935 
link  which  allows  cytotoxic  antibody  produced  by  the  host  to  cause  cell  lysis. 
According  to  this  view,  progressive  growth  of  leukemia  cells  in  AKR  mice 
would not be due to lack of specific cytotoxic antibody but lack of a secondary 
factor (C5)  involved in leukemia cell destruction. Past studies by Kidd  (25) 
and by our group (26) have indicated that complement, not specific antibody, 
may be the limiting factor in determining the effectiveness of immune reactions 
to tumors in the mouse. We have observed that//-2 incompatible ascites sar- 
comas may grow progressively in highly immunized mice (in this case from a 
C5 + strain) even though the tumor cells could be shown to have attached cyto- 
toxic  alloantibody;  injection  of  guinea  pig  serum  as  a  complement  source 
brought about rapid rejection of these far-advanced ascites tumors. Apparently 
the mouse is limited in its capacity to generate sufficient C when called upon 
to reject large numbers of tumor cells.  Thus, complement deficiency (whether 
relative or absolute) can be viewed as another mechanism whereby tumor cells 
escape the consequences of their antigenicity. In this regard, reduced levels of 
complement have  been found in  the  serum  of tumor-bearing mice  (27,  28). 
This provides the most likely explanation for our observation that such sera 
lack antileukemic activity in AKR mice. 
(b)  C5 reacts at some site other than the leukemia cell surface, e.g., with antigen- 
antibody  complexes in the blood or kidney, thus causing the release of lymphokins, 
steroids, etc., that themselves mediate leukemia cell destruction. 
(c)  The antileukemic effect of C5 is independent  of a preexisting  immune re- 
sponse, revealing another mechanism for specific killing of leukemia cells. 
Studies are under way to test  these various possibilities.  Perhaps  the key 
question is whether AKR mice form specific cytotoxic antibodies to autogenous 
leukemia cells.  We are looking for attached immunoglobulins on the surface 
of leukemia cells and for cytotoxic antibody in serum of AKR mice, especially 
after leukemia cell destruction induced by serum, interferon or endotoxin. 
Our studies with CVF reveal that complement appears to be involved, also, 
in the antileukemic activity of interferon and endotoxin. These agents cause a 
remarkable  reduction  in  leukemic  lymph nodes  and  spleen  24  h  after  their 
administration. In leukemic mice, pretreated with CVF, no antileukemic effect 
is seen at 24 h after interferon or endotoxin infusion; by 48 h, however, a pro- 
nounced reduction in leukemic nodes and spleen has occurred. The 24 h delay 
is presumably the  time required for complement levels to return to normal. 
Although complement is known to be involved in other actions of endotoxin, 
such as in the Schwartzman phenomenon (18), no such role has been suggested 
for  complement  in  interferon  action.  It  would  be  important  to  determine 
whether other activities of interferon, e.g., antiviral and antileukemic activity 
in vitro (29), can be modified by CVF or other inhibitors of the complement 
system. Two pathways of complement activation have now been well estab- 
lished, the "classical" pathway (via C1, 4, and 2)  (19)  or through a group of 
serum proteins comprising the properdin or "alternate" pathway (30,  31). In 
both, C5 plays a key roll. If complement is involved in the antileukemic activity 936  SERUM-MEDIATED LEUKEMIA CELL DESTRUCTION 
of interferon and endotoxin, how does this take place in AKR mice which are 
genetically deficient in C5? Is there a  C5  shunt mechanism? Or might  exoge- 
nous interferon  or the interferon (or other factors) induced by endotoxin sub- 
stitute in some way for C5? 
The phenomenon of leukemia cell destruction mediated by normal serum is 
not restricted  to  the mouse.  We have found that  cats with  lymphosarcoma, 
undergo  dramatic  resolution  of  their  disease  when  infused  with  normal  cat 
serum.  Large  lympholnatous masses,  characteristically  of  the  chest  and  ab- 
domen, essentially disappear  after 2 wk of serum infusion on alternate  days. 
8 out of 10 cats so treated have shown this response3 The critical role of com- 
plement in this antileukemic effect in cats needs to be determined. 
These studies in mice and cats suggest that serum-mediated destruction of 
leukemia  cells  may occur in  man,  and  that  the  occasional  remission  after 
blood  transfusion  in  patients  with  leukemia  can  be  explained  on  this  basis. 
Low complement levels  have been observed in the serum of leukemic patients 
(32); this may account for our finding (unpublished)  that serum from 16 of 20 
patients with untreated  leukemia failed  to cause leukemia cell  destruction in 
AKR mice. In view of these several leads,  a closer look at the complement sys- 
tem in patients with leukemia and other cancers is clearly needed. 
SUMMARY 
AKR mice with spontaneous leukemia were infused with normal serum from 
a  variety of species.  Leukemia cell  destruction was produced by serum from 
strains  of mice possessing the full  spectrum of complement components, but 
not  by  serum  from  strains  with  a  genetically  determined  deficiency of  C5. 
Serum from guinea pigs,  horses,  and  humans  also  causes destruction  of leu- 
kemia cells. The antileukemic factor in normal serum was heat labile (56°C for 
35 rain)  and could be inactivated by cobra venom factor (CVF). Tests of indi- 
vidual complement factors from guinea pig serum and from human serum sug- 
gest  that  C5  is  the  antileukemic  complement  component in  normal  serum. 
Evidence was obtained that complement also plays a  role in the antileukemic 
effect of interferon and endotoxin. 
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